Takashi Tadokoro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takashi Tadokoro has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Katsumi Maenaka
Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
4 shared publications - Shunsuke Kita
Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
3 shared publications Hiroki Kusaka
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
2 shared publicationsKengo Hirao
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
2 shared publications- Kimiko Kuroki
Laboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
2 shared publications - Sarah Rowland-Jones
Nuffield Department of Medicine, University of Oxford, Oxford, UK
2 shared publications
Latest Publications
- 1 July 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (1) , 171-179
Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation
Damage-associated molecular patterns (DAMPs) contribute to antitumor immunity during cancer chemotherapy. We previously demonstrated that topotecan (TPT), a topoisomerase I inhibitor, induces DAMP secretion from cancer cells, which activates STING-mediated antitumor immune responses. However, how TPT induces DAMP secretion in cancer cells is yet to be elucidated. Here, we identified RPL15, a 60S ribosomal protein, as a novel TPT target and showed that TPT inhibited preribosomal subunit formation via its binding to RPL15, resulting in the induction of DAMP-mediated antitumor immune activation independent of TOP1. TPT inhibits RPL15–RPL4 interactions and decreases RPL4 stability, which is recovered by CDK12 activity. RPL15 knockdown induced DAMP secretion and increased the CTL population but decreased the regulatory T cell population in a B16-F10 murine melanoma model, which sensitized B16-F10 tumors against PD-1 blockade. Our study identified a novel TPT target protein and showed that ribosomal stress is a trigger of DAMP secretion, which contributes to antitumor immunotherapy. Visual Abstract Key Points RPL15 is identified as a novel TPT target. TPT induces DAMP secretion from cancer cells via its binding to RPL15. RPL15 inhibition sensitizes B16-F10 tumors against PD-1 blockade.
- 1 July 2022
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 209 (1) , 171-179
Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation
Damage-associated molecular patterns (DAMPs) contribute to antitumor immunity during cancer chemotherapy. We previously demonstrated that topotecan (TPT), a topoisomerase I inhibitor, induces DAMP secretion from cancer cells, which activates STING-mediated antitumor immune responses. However, how TPT induces DAMP secretion in cancer cells is yet to be elucidated. Here, we identified RPL15, a 60S ribosomal protein, as a novel TPT target and showed that TPT inhibited preribosomal subunit formation via its binding to RPL15, resulting in the induction of DAMP-mediated antitumor immune activation independent of TOP1. TPT inhibits RPL15–RPL4 interactions and decreases RPL4 stability, which is recovered by CDK12 activity. RPL15 knockdown induced DAMP secretion and increased the CTL population but decreased the regulatory T cell population in a B16-F10 murine melanoma model, which sensitized B16-F10 tumors against PD-1 blockade. Our study identified a novel TPT target protein and showed that ribosomal stress is a trigger of DAMP secretion, which contributes to antitumor immunotherapy. Visual Abstract Key Points RPL15 is identified as a novel TPT target. TPT induces DAMP secretion from cancer cells via its binding to RPL15. RPL15 inhibition sensitizes B16-F10 tumors against PD-1 blockade.
- Open Access
Structure of HIV-2 Nef Reveals Features Distinct from HIV-1 Involved in Immune Regulation
- Open Access
Structure of HIV-2 Nef reveals unique features distinct from HIV-1 involved in immune regulation
Summary: The HIV accessory protein Nef plays a major role in establishing and maintaining infection, particularly through immune evasion. Many HIV-2 infected people experience long-term viral control and survival, resembling HIV-1 elite control. HIV-2 Nef has overlapping but also distinct functions from HIV-1 Nef. Here we report the crystal structure of HIV-2 Nef core. The dileucine sorting motif forms a helix bound to neighboring molecules, and moreover, isothermal titration calorimetry demonstrated that the CD3 endocytosis motif can directly bind to HIV-2 Nef, ensuring AP-2 mediated endocytosis for CD3. The highly-conserved C-terminal region forms a α-helix, absent from HIV-1. We further determined the structure of SIV Nef harboring this region, demonstrating similar C-terminal α-helix, which may contribute to AP-1 binding for MHC-I downregulation. These results provide new insights into the distinct pathogenesis of HIV-2 infection.
Open AccessStructure of HIV-2 Nef reveals unique features distinct from HIV-1 involved in immune regulation
Summary: The HIV accessory protein Nef plays a major role in establishing and maintaining infection, particularly through immune evasion. Many HIV-2 infected people experience long-term viral control and survival, resembling HIV-1 elite control. HIV-2 Nef has overlapping but also distinct functions from HIV-1 Nef. Here we report the crystal structure of HIV-2 Nef core. The dileucine sorting motif forms a helix bound to neighboring molecules, and moreover, isothermal titration calorimetry demonstrated that the CD3 endocytosis motif can directly bind to HIV-2 Nef, ensuring AP-2 mediated endocytosis for CD3. The highly-conserved C-terminal region forms a α-helix, absent from HIV-1. We further determined the structure of SIV Nef harboring this region, demonstrating similar C-terminal α-helix, which may contribute to AP-1 binding for MHC-I downregulation. These results provide new insights into the distinct pathogenesis of HIV-2 infection.
- 1 September 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (2) , 580-585
Establishment of the BacMam system using silkworm baculovirus
- 1 September 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 478 (2) , 580-585
Establishment of the BacMam system using silkworm baculovirus